Tubulis antibody-drug conjugate platform
Acquired in 2026 for a $3.15 billion upfront payment; Q2 2026 included a $3.1 billion acquired R&D charge.
What it is
Tubulis is a Munich-based developer of antibody-drug conjugates, which link antibodies to cancer-killing payloads. Gilead paid $3.15 billion upfront for the company.
Why it matters to the stock. The platform is an oncology bet that could compete with and extend Trodelvy, which is also an antibody-drug conjugate, in later years.
News
Gilead to buy Germany's Tubulis for $3.15 billion upfront, up to $5 billion total
Gilead agreed to buy Munich-based Tubulis, a developer of antibody-drug conjugates, for $3.15 billion in cash at closing plus up to $1.85 billion in milestones.
M&A